Malaria control by chlorproguanil. I. Clinical effects and susceptibility of Plasmodium falciparum in vivo after seven years of monthly chlorproguanil administration to children in a Liberian village.
For seven years, chlorproguanil (1.0 to 2.0 mg kg-1) was administered monthly to the children below 15 years of age in a village with holoendemic malaria. Malariometric indices were recorded every six months. Susceptibility in vivo was monitored by the clearance of Plasmodium falciparum parasitaemia after drug intake. Three parasite species were found initially: P. falciparum (52%), P. malariae (8%) and P. ovale (4%). The parasites found during the study were mainly P. falciparum, and parasite rates ranged from 37 to 87% at the different surveys one month after respective drug intake. A fifty-fold decrease of mean parasite density was generally observed seven days after drug intake. Splenomegaly was initially recorded in all two to nine year old children, with a mean size of 2.64 according to Hackett's index. From 18 months onwards as the mean spleen index was 1.15 in the same age group. Chlorproguanil may represent an important alternative drug to groups at risk in malaria control schemes.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility; D006801:Humans; D007962:Leukocytes / Q000469:parasitology; D007988:Liberia; D008288:Malaria / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D010963:Plasmodium falciparum; D010965:Plasmodium malariae; D002727:Proguanil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013163:Splenomegaly / Q000150:complications
C007030:chlorproguanil; D002727:Proguanil